Compass Pathways PLC (NAS:CMPS)

$ 4.595 0.035 (0.77%) Market Cap: 314.39 Mil Enterprise Value: 139.99 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 38/100

Q3 2024 Compass Pathways PLC Earnings Call Transcript
Oct 31, 2024

$4.76 (-23.10%)

Earnings
Q2 2024 Compass Pathways PLC Earnings Call Transcript
Aug 01, 2024

$6.88 (-9.83%)

Earnings
Q1 2024 Compass Pathways PLC Earnings Call Transcript
May 08, 2024

$8.5 (-0.47%)

Earnings
Q4 2023 Compass Pathways PLC Earnings Call Transcript
Feb 29, 2024

$10.27 (-16.98%)

Earnings
Q3 2023 Compass Pathways PLC Earnings Call Transcript
Nov 02, 2023

$5.95 (+2.94%)

Earnings
Q2 2023 Compass Pathways PLC Earnings Call Transcript
Aug 03, 2023

$8.98 (+0.34%)

Earnings
Compass Pathways PLC CPT III Code Language Discussion Transcript
Jul 11, 2023
Q1 2023 Compass Pathways PLC Earnings Call Transcript
May 11, 2023

$8.52 (-0.81%)

Earnings
Q4 2022 Compass Pathways PLC Earnings Call Transcript
Feb 28, 2023

$8.25 (-2.02%)

Earnings
Q3 2022 Compass Pathways PLC Earnings Call Transcript
Nov 03, 2022

$10.27 (+4.80%)

Earnings
Compass Pathways PLC at Citi BioPharma Conference Transcript
Sep 07, 2022
Q2 2022 Compass Pathways PLC Earnings Call Transcript
Aug 04, 2022

$17.5 (+9.10%)

Earnings
Compass Pathways PLC Annual Shareholders Meeting Transcript
Jun 16, 2022
Compass Pathways PLC at Citi Biopharma Co-Panel Day (Virtual) Transcript
May 18, 2022
Q1 2022 Compass Pathways PLC Earnings Call Transcript
May 10, 2022

$8.2 (+11.41%)

Earnings
Compass Pathways PLC at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022
Full Year 2021 Compass Pathways PLC Earnings Call Transcript
Feb 24, 2022

$13.23 (+4.50%)

Earnings
Compass Pathways PLC at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Q3 2021 Compass Pathways PLC Earnings Call Transcript
Nov 09, 2021

$36 (-16.40%)

Earnings
Compass Pathways PLC at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Compass Pathways PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Compass Pathways PLC Psychedelic Medicines for Mental Health Conditions Panel at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Q2 2021 Compass Pathways PLC Earnings Call Transcript
Aug 11, 2021

$30.16 (-7.63%)

Earnings
Compass Pathways PLC at JMP Securities Life Sciences Virtual Conference Transcript
Jun 16, 2021
Q1 2021 Compass Pathways PLC Earnings Call Transcript
May 13, 2021

$32.79 (-6.31%)

Earnings
Q4 2020 Compass Pathways PLC Earnings Call Transcript
Mar 09, 2021

$44.25 (+12.00%)

Earnings
Q3 2020 Compass Pathways PLC Earnings Call Transcript
Nov 12, 2020

$34.81 (-2.77%)

Earnings

Compass Pathways PLC at Citi BioPharma Conference Transcript

Sep 07, 2022 / 02:30PM GMT

Release Date Price: $15.75 (+1.55%)

Transcript

Neena Marie Bitritto;Garg

Citigroup Inc., Research Division - VP & Analyst

I'm Neena Bitritto-Garg, and I'm one of the biotech analysts here at Citi. I'm very pleased to be joined for our next company panel where we're going to be focusing on mental health and new kind of innovative options for mental health conditions. I've got with me the new CEO of COMPASS Pathways, Kabir Nath; the Chief Medical Officer of Pear Therapeutics, Yuri Maricich; and Florian Brand, the CEO of Atai Life Sciences.

So before we get into Q&A, I want to pass it to each of you to make some opening remarks. And maybe we'll start with Florian.

Florian Brand

Atai Life Sciences N.V. - Co-founder & CEO

Sure, yes. Happy to be here. Thanks for overseeing us. And I think it's a very interesting panel as it combines a range of modalities that we, I think, all are working on, especially with the digital component. And so here is Atai, our biotech -- or biopharmaceutical company in the clinical stage and also heavily believe in the potential of digital

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.